Key Drivers
- Cash generation
- Liquidity pressure
- High leverage
AIAI Summary
Teva has evolved from a simple generic-drug rebound to a credit-improved execution story, where investment-grade ratings and cash flow support the upside, but the stock now hinges on whether UZEDY/AUSTEDO-led branded growth can offset margin pressure and fragile leverage without a cash-conversion miss.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash generation
- •Liquidity pressure
- •High leverage
TEVA delivered a strong 2025 turnaround with solid profitability and cash flow, but the latest quarter showed a loss, weaker liquidity, and high leverage, making the investment case dependent on sustained earnings recovery rather than balance-sheet strength.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Buy-the-dip
- •Overbought stretch
TEVA has held a strong higher-highs/higher-lows uptrend since its late-July low, with support at $35.00-$35.40 and resistance near $36.74-$36.77, though the rally looks extended and may need consolidation if $36.8 stays capped.
Fast rally to new highs suggests short-term overbought conditions
Sentiment & News
Key News Insights:
- •Specialty Growth
- •Guidance Raised
- •Legal Overhang
Teva is showing a broad turnaround as specialty-medicine growth and higher guidance offset generic softness, but investors are still weighing margin improvement against legal overhangs and execution risks.
Teva's improving operating momentum is supportive for the stock, but sustained upside will depend on continued specialty sales growth, margin expansion, and reduced legal uncertainty
Similar Companies in Healthcare
Other companies in the same sector with AI ratings